PMC6700112_01
Tumor with intense HER2/Neu 3+ positivity on immunohistochemistry (scale 50 mum)
41698_2019_91_Fig1_HTML.jpg
PMC6700112_01_41698_2019_91_Fig1_HTML.jpg
Fig1
Guardant360 testing showed ERBB2 (HER2) amplification 3+ and was confirmed through tumor tissue-based immunohistochemistry as well as genetic testing through the commercially available platform by Tempus confirming this (Fig. 1).
MRI pre- and post-treatment with decreased size and enhancement of lesions in liver
41698_2019_91_Fig2_HTML.jpg
PMC6700112_01_41698_2019_91_Fig2_HTML.jpg
Fig2
Scans also showed excellent ongoing durable response (Fig. 2a, b).